A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Preliminary clinical data.
Emmanuel S. Antonarakis
Consultant or Advisory Role - Dendreon
Research Funding - Dendreon
Adam Stuart Kibel
Consultant or Advisory Role - Dendreon; Myriad Genetics; Sanofi
George W. Adams
Honoraria - Amgen; Dendreon
Lawrence Ivan Karsh
Consultant or Advisory Role - Dendreon
Honoraria - Dendreon
Research Funding - Dendreon
Aymen Elfiky
No relevant relationships to disclose
Neal D. Shore
Consultant or Advisory Role - Algeta; Astellas Pharma; Bayer; Janssen; Medivation; Millennium; Pfizer; Sanofi
Research Funding - Algeta; Astellas Pharma; Bayer; Janssen; Medivation; Millennium; Pfizer; Sanofi
Nicholas J. Vogelzang
Consultant or Advisory Role - Dendreon
Research Funding - Dendreon
John M. Corman
Research Funding - Dendreon
Robert Claude Tyler
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Candice McCoy
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Todd DeVries
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Nadeem A. Sheikh
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Charles G. Drake
Consultant or Advisory Role - Bristol-Myers Squibb; Dendreon; Janssen; Pfizer; Roche
Research Funding - Aduro Biotech; Bristol-Myers Squibb